Safety and Efficacy of Delayed-release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from Asia-Pacific and Other Countries: Interim Analysis of the APEX Extension Study

被引：0
|
作者：
Saida, Takahiko [1 ]
Yamamura, Takashi [2 ]
Kondo, Takayuki [3 ]
Yun, Jang [4 ]
Li, Jie [4 ]
Forsythe, Beverley [4 ]
Sheikh, Sarah, I [4 ]
Zhu, Bing [4 ]
机构：
[1] Kyoto Min Iren Cent Hosp, Kansai Multiple Sclerosis Ctr, Kyoto, Japan
[2] Natl Ctr Neurol & Psychiat NCNP, Tokyo, Japan
[3] Kansai Med Univ, Med Ctr, Osaka, Japan
[4] Biogen, Cambridge, MA USA
来源：
NEUROLOGY | 2017年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P5.363
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Budget impact analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Marchesi, Chiara
    Santoni, Laura
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (01) : 29 - 39
  • [22] Efficacy and safety of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis patients with cardiovascular disease: integrated analysis of the phase 3 DEFINE and CONFIRM studies
    Havrdova, E.
    Fox, R. J.
    Gold, R.
    Li, J.
    Zhang, A.
    Potts, J.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 551 - 552
  • [23] The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
    Su, Wenqing
    Kansal, Anuraag
    Vicente, Colin
    Deniz, Baris
    Sarda, Sujata
    JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (07) : 718 - 727
  • [24] Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE
    Gold, Ralf
    Arnold, Douglas L.
    Bar-Or, Amit
    Fox, Robert J.
    Kappos, Ludwig
    Chen, Chongshu
    Parks, Becky
    Miller, Catherine
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [25] A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis
    Allan, Michelle
    Grant, Lindsay
    NEUROLOGY AND THERAPY, 2020, 9 (01) : 85 - 92
  • [26] Delayed-release Dimethyl Fumarate Demonstrates Sustained Efficacy over Nine Years in Newly Diagnosed Patients with Relapsing-Remitting Multiple Sclerosis
    Gold, Ralf
    Giovannoni, Gavin
    Phillips, J. Theodore
    Bar-Or, Amit
    Fox, Robert J.
    Chen, Chongshu
    Miller, Catherine
    NEUROLOGY, 2019, 92 (15)
  • [27] Delayed-release dimethyl fumarate demonstrates sustained efficacy over nine years in newly diagnosed patients with relapsing-remitting multiple sclerosis
    Gold, R.
    Giovannoni, G.
    Phillips, J. T.
    Bar-Or, A.
    Fox, R. J.
    Chen, C.
    Miller, C.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 498 - 499
  • [28] Cost-effectiveness analysis of delayed-release dimethyl-fumarate in the treatment of relapsing-remitting multiple sclerosis in Italy
    Furneri, Gianluca
    Santoni, Laura
    Marchesi, Chiara
    Iannazzo, Sergio
    Cortesi, Paolo Angelo
    Piacentini, Patrizio
    Caputi, Achille Patrizio
    Mantovani, Lorenzo Giovanni
    FARMECONOMIA-HEALTH ECONOMICS AND THERAPEUTIC PATHWAYS, 2016, 17 (02) : 67 - 80
  • [29] COST-EFFECTIVENESS ANALYSIS OF DELAYED-RELEASE DIMETHYL-FUMARATE IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN ITALY
    Fumeri, G.
    Santoni, L.
    Marchesi, C.
    Iannazzo, S.
    Cortesi, R.
    Piacentini, P.
    Caputi, A.
    Mantovani, L. G.
    VALUE IN HEALTH, 2015, 18 (07) : A697 - A697
  • [30] Interim Results of an Open-Label Study to Assess the Effects of Delayed-release Dimethyl Fumarate on Lymphocyte Subsets and Immunoglobulins in Patients with Relapsing-remitting Multiple Sclerosis
    Von Hehn, Christian
    Mehta, Devangi
    Prada, Claudia
    Yang, Lili
    Liu, Shifang
    Ray, Soma
    Sheikh, Sarah
    NEUROLOGY, 2017, 88
12345